Mild to moderate Alzheimer dementia with insufficient neuropathological changes

Alberto Serrano-Pozo; Jing Qian; Sarah E. Monsell; Deborah Blacker; Teresa Gómez-Isla; Rebecca A. Betensky; John H. Growdon; Keith A. Johnson; Matthew P. Frosch; Reisa A. Sperling; Bradley T. Hyman

doi:10.1002/ana.24125

Mild to moderate Alzheimer dementia with insufficient neuropathological changes

Alberto Serrano-Pozo
, Jing Qian
, Sarah E. Monsell
, Deborah Blacker
, Teresa Gómez-Isla
, Rebecca A. Betensky
, John H. Growdon
, Keith A. Johnson
, Matthew P. Frosch
, Reisa A. Sperling
, Bradley T. Hyman

Research output: Contribution to journal › Article › peer-review

105 Scopus citations

Abstract

Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

Original language	English
Pages (from-to)	597-601
Number of pages	5
Journal	Annals of Neurology
Volume	75
Issue number	4
DOIs	https://doi.org/10.1002/ana.24125
State	Published - Apr 2014
Externally published	Yes

Access to Document

10.1002/ana.24125

Cite this

@article{9f981640ef3d4bd89ccd0701080d6c9f,

title = "Mild to moderate Alzheimer dementia with insufficient neuropathological changes",

abstract = "Recently, ∼16\% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14\% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these {"}Aβ-negative{"} subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601",

author = "Alberto Serrano-Pozo and Jing Qian and Monsell, \{Sarah E.\} and Deborah Blacker and Teresa G{\'o}mez-Isla and Betensky, \{Rebecca A.\} and Growdon, \{John H.\} and Johnson, \{Keith A.\} and Frosch, \{Matthew P.\} and Sperling, \{Reisa A.\} and Hyman, \{Bradley T.\}",

year = "2014",

month = apr,

doi = "10.1002/ana.24125",

language = "English",

volume = "75",

pages = "597--601",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley \& Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Mild to moderate Alzheimer dementia with insufficient neuropathological changes

AU - Serrano-Pozo, Alberto

AU - Qian, Jing

AU - Monsell, Sarah E.

AU - Blacker, Deborah

AU - Gómez-Isla, Teresa

AU - Betensky, Rebecca A.

AU - Growdon, John H.

AU - Johnson, Keith A.

AU - Frosch, Matthew P.

AU - Sperling, Reisa A.

AU - Hyman, Bradley T.

PY - 2014/4

Y1 - 2014/4

N2 - Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

AB - Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

UR - https://www.scopus.com/pages/publications/84899981521

U2 - 10.1002/ana.24125

DO - 10.1002/ana.24125

M3 - Article

C2 - 24585367

AN - SCOPUS:84899981521

SN - 0364-5134

VL - 75

SP - 597

EP - 601

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

Mild to moderate Alzheimer dementia with insufficient neuropathological changes

Abstract

Access to Document

Fingerprint

Cite this